Measuring reproducibility of regional brain metabolic responses to lorazepam using statistical parametric maps

Gene Jack Wang, Nora D. Volkow, Alejandro V. Levy, Christoph A. Felder, Joanna S. Fowler, Naomi R. Pappas, Robert Hitzemann, Christopher T. Wong

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Statistical parametric mapping (SPM) is a method for localizing differences in brain activation patterns without the need for anatomic predefined constraints. The purpose of this study was to assess the reproducibility of the patterns of activation obtained with SPM for baseline measures and for metabolic changes in response to lorazepam on a test-retest design. The results were compared with those we previously published using region-of-interest (ROI) methods. Methods: Sixteen healthy right-handed men were scanned twice with PET and [18SF]fluorodeoxyglucose (FDG): before placebo and before lorazepam (30 μg/kg). The same double FDG procedure was repeated 6-8 wk later to assess test-retest reproducibility. Image datasets were analyzed by using SPM95 software. Difference images between baseline and lorazepam were compared for the first and second evaluations, both for relative decreases as well as increases in metabolism. Significance level was systematically varied to P <0.001, P <0.01 and P <0.05. Results: There were no differences in the baseline SPM maps obtained for the first and second evaluations. SPM showed similar, although not identical, differences in response to lorazepam between the two evaluations. Both evaluations showed significant decreases in occipital codex (9.7% and 10%) and significant relative increases in left temporal pole (6.8% and 10.4%). However, the second evaluation showed a decrease in the left frontal cortex (areas 6 and 8), which was not present in the first evaluation. The results were very similar to those we had obtained with ROI methods, except for the activation in the left temporal pole, which we had not observed with ROI analyses. Conclusion: Although the overall pattern of lorazepam-induced activation depicted by SPM was reproducible in pattern and magnitude, there were some differences that included a left frontal area of deactivation during the second but not the first evaluation. Results with SPM are similar to those with the ROI method, and, because it systematically analyses the whole brain, SPM can uncover patterns not seen with the ROI method.

Original languageEnglish (US)
Pages (from-to)715-720
Number of pages6
JournalJournal of Nuclear Medicine
Volume40
Issue number5
StatePublished - May 1999
Externally publishedYes

Fingerprint

Lorazepam
Brain
Frontal Lobe
Software
Placebos

Keywords

  • Benzodiazepines
  • Cerebral glucose metabolism
  • Fluorodeoxyglucose
  • PET
  • Statistical parametric mapping

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Wang, G. J., Volkow, N. D., Levy, A. V., Felder, C. A., Fowler, J. S., Pappas, N. R., ... Wong, C. T. (1999). Measuring reproducibility of regional brain metabolic responses to lorazepam using statistical parametric maps. Journal of Nuclear Medicine, 40(5), 715-720.

Measuring reproducibility of regional brain metabolic responses to lorazepam using statistical parametric maps. / Wang, Gene Jack; Volkow, Nora D.; Levy, Alejandro V.; Felder, Christoph A.; Fowler, Joanna S.; Pappas, Naomi R.; Hitzemann, Robert; Wong, Christopher T.

In: Journal of Nuclear Medicine, Vol. 40, No. 5, 05.1999, p. 715-720.

Research output: Contribution to journalArticle

Wang, GJ, Volkow, ND, Levy, AV, Felder, CA, Fowler, JS, Pappas, NR, Hitzemann, R & Wong, CT 1999, 'Measuring reproducibility of regional brain metabolic responses to lorazepam using statistical parametric maps', Journal of Nuclear Medicine, vol. 40, no. 5, pp. 715-720.
Wang GJ, Volkow ND, Levy AV, Felder CA, Fowler JS, Pappas NR et al. Measuring reproducibility of regional brain metabolic responses to lorazepam using statistical parametric maps. Journal of Nuclear Medicine. 1999 May;40(5):715-720.
Wang, Gene Jack ; Volkow, Nora D. ; Levy, Alejandro V. ; Felder, Christoph A. ; Fowler, Joanna S. ; Pappas, Naomi R. ; Hitzemann, Robert ; Wong, Christopher T. / Measuring reproducibility of regional brain metabolic responses to lorazepam using statistical parametric maps. In: Journal of Nuclear Medicine. 1999 ; Vol. 40, No. 5. pp. 715-720.
@article{bd562045cff14fcca9c1da4d7d50e468,
title = "Measuring reproducibility of regional brain metabolic responses to lorazepam using statistical parametric maps",
abstract = "Statistical parametric mapping (SPM) is a method for localizing differences in brain activation patterns without the need for anatomic predefined constraints. The purpose of this study was to assess the reproducibility of the patterns of activation obtained with SPM for baseline measures and for metabolic changes in response to lorazepam on a test-retest design. The results were compared with those we previously published using region-of-interest (ROI) methods. Methods: Sixteen healthy right-handed men were scanned twice with PET and [18SF]fluorodeoxyglucose (FDG): before placebo and before lorazepam (30 μg/kg). The same double FDG procedure was repeated 6-8 wk later to assess test-retest reproducibility. Image datasets were analyzed by using SPM95 software. Difference images between baseline and lorazepam were compared for the first and second evaluations, both for relative decreases as well as increases in metabolism. Significance level was systematically varied to P <0.001, P <0.01 and P <0.05. Results: There were no differences in the baseline SPM maps obtained for the first and second evaluations. SPM showed similar, although not identical, differences in response to lorazepam between the two evaluations. Both evaluations showed significant decreases in occipital codex (9.7{\%} and 10{\%}) and significant relative increases in left temporal pole (6.8{\%} and 10.4{\%}). However, the second evaluation showed a decrease in the left frontal cortex (areas 6 and 8), which was not present in the first evaluation. The results were very similar to those we had obtained with ROI methods, except for the activation in the left temporal pole, which we had not observed with ROI analyses. Conclusion: Although the overall pattern of lorazepam-induced activation depicted by SPM was reproducible in pattern and magnitude, there were some differences that included a left frontal area of deactivation during the second but not the first evaluation. Results with SPM are similar to those with the ROI method, and, because it systematically analyses the whole brain, SPM can uncover patterns not seen with the ROI method.",
keywords = "Benzodiazepines, Cerebral glucose metabolism, Fluorodeoxyglucose, PET, Statistical parametric mapping",
author = "Wang, {Gene Jack} and Volkow, {Nora D.} and Levy, {Alejandro V.} and Felder, {Christoph A.} and Fowler, {Joanna S.} and Pappas, {Naomi R.} and Robert Hitzemann and Wong, {Christopher T.}",
year = "1999",
month = "5",
language = "English (US)",
volume = "40",
pages = "715--720",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "5",

}

TY - JOUR

T1 - Measuring reproducibility of regional brain metabolic responses to lorazepam using statistical parametric maps

AU - Wang, Gene Jack

AU - Volkow, Nora D.

AU - Levy, Alejandro V.

AU - Felder, Christoph A.

AU - Fowler, Joanna S.

AU - Pappas, Naomi R.

AU - Hitzemann, Robert

AU - Wong, Christopher T.

PY - 1999/5

Y1 - 1999/5

N2 - Statistical parametric mapping (SPM) is a method for localizing differences in brain activation patterns without the need for anatomic predefined constraints. The purpose of this study was to assess the reproducibility of the patterns of activation obtained with SPM for baseline measures and for metabolic changes in response to lorazepam on a test-retest design. The results were compared with those we previously published using region-of-interest (ROI) methods. Methods: Sixteen healthy right-handed men were scanned twice with PET and [18SF]fluorodeoxyglucose (FDG): before placebo and before lorazepam (30 μg/kg). The same double FDG procedure was repeated 6-8 wk later to assess test-retest reproducibility. Image datasets were analyzed by using SPM95 software. Difference images between baseline and lorazepam were compared for the first and second evaluations, both for relative decreases as well as increases in metabolism. Significance level was systematically varied to P <0.001, P <0.01 and P <0.05. Results: There were no differences in the baseline SPM maps obtained for the first and second evaluations. SPM showed similar, although not identical, differences in response to lorazepam between the two evaluations. Both evaluations showed significant decreases in occipital codex (9.7% and 10%) and significant relative increases in left temporal pole (6.8% and 10.4%). However, the second evaluation showed a decrease in the left frontal cortex (areas 6 and 8), which was not present in the first evaluation. The results were very similar to those we had obtained with ROI methods, except for the activation in the left temporal pole, which we had not observed with ROI analyses. Conclusion: Although the overall pattern of lorazepam-induced activation depicted by SPM was reproducible in pattern and magnitude, there were some differences that included a left frontal area of deactivation during the second but not the first evaluation. Results with SPM are similar to those with the ROI method, and, because it systematically analyses the whole brain, SPM can uncover patterns not seen with the ROI method.

AB - Statistical parametric mapping (SPM) is a method for localizing differences in brain activation patterns without the need for anatomic predefined constraints. The purpose of this study was to assess the reproducibility of the patterns of activation obtained with SPM for baseline measures and for metabolic changes in response to lorazepam on a test-retest design. The results were compared with those we previously published using region-of-interest (ROI) methods. Methods: Sixteen healthy right-handed men were scanned twice with PET and [18SF]fluorodeoxyglucose (FDG): before placebo and before lorazepam (30 μg/kg). The same double FDG procedure was repeated 6-8 wk later to assess test-retest reproducibility. Image datasets were analyzed by using SPM95 software. Difference images between baseline and lorazepam were compared for the first and second evaluations, both for relative decreases as well as increases in metabolism. Significance level was systematically varied to P <0.001, P <0.01 and P <0.05. Results: There were no differences in the baseline SPM maps obtained for the first and second evaluations. SPM showed similar, although not identical, differences in response to lorazepam between the two evaluations. Both evaluations showed significant decreases in occipital codex (9.7% and 10%) and significant relative increases in left temporal pole (6.8% and 10.4%). However, the second evaluation showed a decrease in the left frontal cortex (areas 6 and 8), which was not present in the first evaluation. The results were very similar to those we had obtained with ROI methods, except for the activation in the left temporal pole, which we had not observed with ROI analyses. Conclusion: Although the overall pattern of lorazepam-induced activation depicted by SPM was reproducible in pattern and magnitude, there were some differences that included a left frontal area of deactivation during the second but not the first evaluation. Results with SPM are similar to those with the ROI method, and, because it systematically analyses the whole brain, SPM can uncover patterns not seen with the ROI method.

KW - Benzodiazepines

KW - Cerebral glucose metabolism

KW - Fluorodeoxyglucose

KW - PET

KW - Statistical parametric mapping

UR - http://www.scopus.com/inward/record.url?scp=0032943031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032943031&partnerID=8YFLogxK

M3 - Article

VL - 40

SP - 715

EP - 720

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 5

ER -